A5084805118- Treatment of Major Depression
- Tryptophan and brain disorders
- Functional Brain Connectivity Studies
- Mental Health Research Topics
- COVID-19 and Mental Health
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Memory and Neural Mechanisms
- Neurotransmitter Receptor Influence on Behavior
- Healthcare professionals’ stress and burnout
- Latin American history and culture
- Neuroscience and Neuropharmacology Research
- Electroconvulsive Therapy Studies
- Occupational Health and Burnout
Complexo Hospitalar Universitário Professor Edgard Santos
2020-2023
Universidade Federal da Bahia
2018-2023
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2021
Université Paris Nanterre
2019
Introduction: The use of ketamine as an option in the treatment depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, S (+) enantiomer ketamine, most widely used form anesthetic environment some countries, new studies have shown that it may also be effective depression with better tolerability. However, no study so far has directly compared esketamine racemic ketamine. Here we propose a protocol trial to evaluate...
Abstract Background Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) characterized by the failure at least one adequate trial major class antidepressant, with time dosage. We aimed to identify clinical predictors remission response 24 h 7 days after racemic ketamine esketamine infusions. Methods A randomized, double‐blind, active‐controlled, non‐inferiority using in TRD....
In 2020, the COVID-19 pandemic brought a work and stress overload to healthcare workers, increasing their vulnerability mental health impairments. response, authors created COMVC-19 program. The program offered preventive actions treatment for 22,000 workers of Hospital das Clinicas da Faculdade de Medicina Universidade São Paulo (HCFMUSP). This paper aims describe its implementation share what we have learned from this experience.Workers were able easily access through 24/7 hotline....
Background Ketamine and esketamine have both shown significant antidepressant effects in treatment-resistant depression (TRD), conflicting evidence suggests that induced dissociation by these drugs can be a clinical predictor of esketamine/ketamine's efficacy.
Evidence suggests that ketamine's influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact ketamine and esketamine serum BDNF levels association with response patterns treatment-resistant depression (TRD).